RIT1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

RIT1 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].